A Prospective, Multicenter, Phase-II Trial of Ibrutinib Plus Venetoclax in Patients With Creatinine Clearance >= 30 ml/Min Who Have Relapsed or Refractory Chronic Lymphocytic Leukemia (RR-CLL) With or Without TP53 Aberrations

NCT03226301 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

230

Enrollment

OTHER

Sponsor class

Conditions

Chronic Lymphocytic Leukemia in Relapse
Chronic Lymphocytic Leukemia in Remission

Interventions

DRUG: Ibrutinib + Venetoclax 15 cycles
DRUG: Ibrutinib until progression/relapse
DRUG: Possible reinitiation treatment: Ibrutinib + Venetoclax 12 cycles

Sponsor

Stichting Hemato-Oncologie voor Volwassenen Nederland

Collaborators

[object Object]